Litigation Details for Pfizer Inc. v. Natco Pharma, Inc. (D. Del. 2021)

« Back to Dashboard

Pfizer Inc. v. Natco Pharma, Inc. (D. Del. 2021)

Docket		Date Filed	2021-08-16
Court	District Court, D. Delaware	Date Terminated	2022-04-08
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,723,730; RE47,739
Link to Docket	External link to docket

Details for Pfizer Inc. v. Natco Pharma, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-16				External link to document

Pfizer Inc. v. Natco Pharma, Inc. Litigation Summary: Vyndaqel Tafamidis Patent Case, 1:21-cv-01179

Last updated: October 16, 2026

Pfizer Inc. v. Natco Pharma Ltd., No. 1:21-cv-01179, was a Hatch-Waxman patent case filed in the U.S. District Court for the District of Delaware concerning Natco’s proposed generic version of Pfizer’s Vyndaqel product, which contains tafamidis meglumine. Pfizer brought the action after Natco submitted an abbreviated new drug application, or ANDA, to the FDA with a Paragraph IV certification against Pfizer’s listed patents.

The case was part of Pfizer’s broader effort to protect tafamidis products from generic competition. The litigation risk centered on formulation and method-of-use patent claims rather than only the original tafamidis compound. The docket proceeded as a pharmaceutical patent action and was resolved without a merits judgment establishing invalidity or noninfringement.

What drug and patents were at issue in Pfizer v. Natco?

The case concerned Vyndaqel, Pfizer’s tafamidis meglumine product used to treat transthyretin amyloidosis. Vyndaqel was approved in the United States in 2011 for cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis in adults. Pfizer later commercialized Vyndamax, which contains tafamidis free acid.

Item	Detail
Brand	Vyndaqel
Active ingredient	Tafamidis meglumine
Related Pfizer product	Vyndamax
Therapeutic area	Transthyretin amyloidosis
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01179
Plaintiff	Pfizer Inc.
Defendant	Natco Pharma Ltd.
Docket judge	Richard G. Andrews
Filing period	2021
Principal issue	Natco’s proposed generic tafamidis product and Pfizer’s listed patent rights

Pfizer’s complaint alleged that Natco’s ANDA product would infringe patents protecting tafamidis products and their use. The asserted patent portfolio included U.S. Patent No. 10,183,020, which was directed to tafamidis-related pharmaceutical subject matter and was listed in connection with Pfizer’s tafamidis products. The scope of the asserted claims, including any additional patents identified in the complaint or amended pleadings, controlled the case’s technical and legal exposure. (Pfizer Inc. v. Natco Pharma Ltd., 2021).

Why did Pfizer sue Natco under the Hatch-Waxman Act?

Pfizer sued after Natco certified under Paragraph IV that one or more patents listed for Vyndaqel were invalid, unenforceable, or would not be infringed by Natco’s proposed product. A Paragraph IV certification is an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing the brand manufacturer to file suit before the generic product reaches the market.

The filing of the lawsuit generally triggered a 30-month stay of FDA approval for Natco’s ANDA, subject to statutory exceptions. The stay delayed final approval unless the court resolved the case earlier, the patents expired, or the parties reached a settlement that permitted an earlier launch.

The case therefore had two commercial objectives:

1. Preserve Pfizer’s tafamidis revenue during the patent term.
2. Prevent Natco from obtaining final FDA approval or launching before the agreed or adjudicated entry date.

What patents protect Vyndaqel and tafamidis?

Vyndaqel’s patent protection has several layers:

Tafamidis compound protection

The earliest protection for tafamidis arose from compound and pharmaceutical composition claims. Those rights have less commercial force once their patent terms expire or once generic applicants can design around the relevant claims.

Tafamidis meglumine and product protection

Vyndaqel contains tafamidis meglumine, a salt form of tafamidis. Salt-form, composition, dosage-form, and pharmaceutical preparation claims can create a separate barrier from the original active-ingredient patent.

The distinction between tafamidis meglumine and tafamidis free acid also matters commercially. Vyndaqel and Vyndamax are related products, but their formulations and regulatory descriptions are not identical. A generic applicant must show that its ANDA product corresponds to the reference listed drug identified in the application. Pfizer can assert infringement based on the formulation, salt, manufacturing process, or product characteristics described in the generic application.

Method-of-use protection

Pfizer also relied on method-of-use rights covering the treatment of transthyretin amyloidosis. Method-of-use patents can remain commercially relevant after compound protection expires if the generic applicant’s labeling induces use for the patented indication.

A generic applicant may attempt to avoid infringement through a section viii statement, sometimes called a skinny label, that omits patented indications. That strategy is more difficult where the FDA-approved label, prescriber behavior, or product marketing would still encourage the patented use.

What was the procedural history of the case?

The material procedural sequence was:

Date or period	Event
2021	Natco submitted an ANDA for a proposed generic tafamidis product and served Pfizer with a Paragraph IV certification.
2021	Pfizer filed the infringement action in the District of Delaware.
2021-2022	The parties proceeded through pleadings and Hatch-Waxman discovery.
2022-2023	The case was resolved through a non-merits disposition reflected on the docket.
After resolution	No public trial judgment established that the asserted patents were invalid or not infringed.

The case ended without a reported claim-construction ruling, trial verdict, or Federal Circuit decision determining the validity or infringement of the asserted tafamidis patent claims. The absence of a merits ruling limits the precedential value of the case.

Did Natco file a Paragraph IV challenge?

Yes. The litigation was based on Natco’s Paragraph IV certification concerning Pfizer’s listed tafamidis patents. The certification put patent validity, enforceability, and infringement directly at issue before commercial launch.

A Paragraph IV challenge can create substantial value for a generic company even when the litigation later settles. The generic applicant obtains leverage over the brand company’s launch timetable, while the brand company must assess the risk that the asserted claims will fail under claim construction, written description, enablement, obviousness, anticipation, or noninfringement theories.

The public case record does not establish that Natco prevailed on any invalidity or noninfringement defense. The case’s termination therefore should not be treated as a judicial finding against Pfizer’s patent estate.

What was the litigation status and outcome?

Pfizer v. Natco was resolved without a reported adjudication on the merits. The docket does not provide a trial judgment invalidating Pfizer’s asserted patents or finding that Natco’s ANDA product was noninfringing.

The resolution appears to have been a negotiated disposition rather than a litigated defeat for Pfizer. The public docket does not disclose the full commercial terms of the parties’ agreement. As a result, the exact Natco launch date, any authorized-generic provisions, supply terms, patent-license terms, and restrictions on Natco’s product activities cannot be determined from the public merits record alone.

The key business point is that the case did not produce an immediate public generic launch authorization comparable to a judgment clearing Natco to enter the market.

Was there a settlement agreement?

The action concluded through a settlement-related disposition. The substantive settlement terms were not publicly disclosed in the docket materials sufficient to establish a complete economic reconstruction.

In pharmaceutical patent cases, a settlement may contain several provisions:

• A licensed launch date before patent expiration.
• A later launch date tied to a separate patent.
• An authorized-generic arrangement.
• A supply agreement.
• Restrictions on marketing or manufacturing.
• A covenant not to sue covering specific dosage forms or indications.
• A license limited to the particular ANDA formulation.

The absence of public terms means that the case should not be classified solely as a win for Pfizer or Natco. The legal outcome preserved negotiated flexibility, while the commercial outcome depends on the scope of any license and the remaining patent and regulatory barriers.

What is the FDA and Orange Book status of Vyndaqel?

Vyndaqel is an FDA-approved prescription product. FDA approval does not eliminate patent exposure, and Orange Book listing does not by itself establish that a listed patent is valid or infringed.

The Orange Book identifies patents and regulatory exclusivity information submitted by the NDA holder. For a generic applicant, the listed patents determine the certification options under 21 U.S.C. § 355(j):

• Paragraph I: no patent information is listed.
• Paragraph II: the listed patent has expired.
• Paragraph III: the applicant will wait until patent expiration.
• Paragraph IV: the patent is invalid, unenforceable, or not infringed.
• Section viii statement: the applicant seeks approval only for uses not covered by the listed method-of-use patent.

Natco’s Paragraph IV filing created the statutory basis for Pfizer’s action. The FDA’s final approval timing would depend on the 30-month stay, patent expiration, court resolution, settlement terms, and any applicable regulatory exclusivity.

When does tafamidis lose exclusivity?

Tafamidis does not have one single exclusivity date. Commercial protection depends on separate patent claims and FDA exclusivity periods.

Protection category	Relevance to Vyndaqel
Original compound patent	Protects tafamidis as an active ingredient, subject to patent-term expiration and any patent-term adjustment.
Salt or composition patent	Protects tafamidis meglumine or related pharmaceutical compositions.
Formulation patent	May cover dosage form, excipients, dissolution, stability, or product characteristics.
Method-of-use patent	May protect treatment of transthyretin amyloidosis or a related patient population.
FDA exclusivity	Operates independently from patent rights and may affect approval timing.
Pediatric exclusivity	Can add six months to qualifying patent and regulatory protections.

The expiration of an early tafamidis patent would not necessarily authorize generic Vyndaqel entry if later-listed and enforceable patents remained in force. Conversely, a generic applicant may challenge later patents through Paragraph IV litigation or avoid some method-of-use claims through labeling restrictions.

How strong was Pfizer’s patent estate?

Pfizer’s estate had meaningful defensive strength because it did not depend on a single patent category. The combination of composition, formulation, and method-of-use rights increased the number of legal pathways available to delay or condition generic entry.

Its principal strengths were:

• A branded product with a defined FDA reference product.
• Patent claims directed to the marketed tafamidis product.
• Potential method-of-use coverage for a specialized, high-value indication.
• A limited number of technically sophisticated generic competitors.
• High clinical and commercial value attached to uninterrupted supply.

The main weaknesses were typical of pharmaceutical patent estates:

• Older compound claims face expiration and prior-art attacks.
• Salt and formulation claims may face obviousness challenges.
• Method-of-use claims may be vulnerable to skinny-label strategies.
• A patent covering a narrow formulation may not block all alternative products.
• A settlement eliminates the opportunity to obtain a favorable judicial precedent.

The case did not generate a published opinion that tested these issues. Patent strength must therefore be evaluated from the claim scope, prosecution history, Orange Book listings, and related litigation rather than from a final judicial ruling.

What generic entry risks exist for Vyndaqel?

The principal generic-entry risks are timing risk, product-substitution risk, and indication risk.

Timing risk

Natco’s ANDA could not proceed to unrestricted commercial launch while the statutory stay and enforceable patent barriers remained in place. A settlement may have converted an uncertain litigation timetable into a defined license date.

Product-substitution risk

Vyndaqel and Vyndamax have different product presentations. Generic entry against one product does not automatically eliminate all protection for the other. Pfizer may continue to defend a separate formulation or product configuration.

Indication risk

Tafamidis is used for a specialized disease population. Generic substitution may be slower than in high-volume primary-care markets if prescriber control, payer restrictions, specialty distribution, or diagnosis requirements limit substitution.

Manufacturing and supply risk

Tafamidis products require controlled pharmaceutical manufacturing and regulatory compliance. Manufacturing know-how may not create a standalone statutory barrier, but process patents, API supply, quality requirements, and FDA inspection readiness can delay a generic launch.

How does this case compare with ordinary small-molecule generic litigation?

Pfizer v. Natco involved a small-molecule drug, not a biologic. Biosimilar litigation under the Biologics Price Competition and Innovation Act was therefore not the governing framework. Natco pursued an ANDA rather than a biosimilar application.

Issue	Tafamidis case	Biosimilar case
FDA pathway	ANDA	351(k) biologics license application
Core legal framework	Hatch-Waxman	BPCIA
Patent notice	Paragraph IV certification	Patent dance and BPCIA notice
Product type	Small molecule	Biologic
Substitution	State generic-substitution rules may apply	Interchangeability and state substitution rules
Main patent disputes	Composition, formulation, method of use	Product, process, manufacturing, and clinical similarity claims

The absence of biosimilar risk does not eliminate competition risk. For tafamidis, the relevant threat is conventional generic entry through an ANDA.

What was the commercial exposure to Pfizer?

Tafamidis became one of Pfizer’s major growth products. Vyndaqel and Vyndamax sales generated several billion dollars annually in the early 2020s, driven by expanded diagnosis of transthyretin amyloid cardiomyopathy and increased treatment duration. Pfizer reported combined Vyndaqel-family revenues of approximately $3.3 billion in 2023 and approximately $4.1 billion in 2024. (Pfizer Inc., 2024, 2025).

That revenue concentration increased the value of each additional year of market protection. The case was commercially significant even if Natco’s eventual market share would have been limited. A generic tafamidis product could pressure:

• Net price and payer rebates.
• Specialty-pharmacy economics.
• Patient-assistance spending.
• Prescriber retention.
• Conversion between Vyndaqel and Vyndamax.
• Pfizer’s forecast for its Internal Medicine portfolio.

The magnitude of exposure depends on the agreed launch date, the number of competing ANDA filers, the FDA’s final approval timing, and whether Pfizer maintains separate protection for Vyndamax.

Key Takeaways

• Pfizer Inc. v. Natco Pharma Ltd., No. 1:21-cv-01179, was a Delaware Hatch-Waxman case involving Natco’s proposed generic tafamidis product.
• The branded reference product was Vyndaqel, containing tafamidis meglumine.
• Pfizer asserted patent rights directed to tafamidis-related pharmaceutical subject matter, including formulation and treatment-use protection.
• Natco’s Paragraph IV certification triggered the infringement action and the statutory FDA approval stay.
• The case ended without a reported trial verdict or merits decision invalidating Pfizer’s patents.
• The settlement-related resolution did not publicly disclose the complete launch timetable or economic terms.
• Tafamidis remains exposed to conventional generic competition, not biosimilar competition.
• Pfizer’s commercial exposure is substantial because Vyndaqel and Vyndamax generate multi-billion-dollar annual revenue.
• Generic entry analysis must account for Orange Book patents, product differences between Vyndaqel and Vyndamax, method-of-use labeling, and any confidential settlement license.

FAQs

What was Pfizer v. Natco 1:21-cv-01179 about?

It was a Hatch-Waxman patent lawsuit concerning Natco’s ANDA for a generic tafamidis product corresponding to Pfizer’s Vyndaqel.

Did Natco invalidate Pfizer’s Vyndaqel patents?

No reported merits judgment in the case invalidated Pfizer’s asserted patents or found them not infringed.

Is tafamidis a biologic requiring biosimilar approval?

No. Tafamidis is a small-molecule drug and generic applicants use the ANDA pathway.

Does a generic Vyndaqel automatically replace Vyndamax?

No. Vyndaqel contains tafamidis meglumine, while Vyndamax contains tafamidis free acid. The products have related but distinct regulatory and formulation profiles.

Are the Pfizer-Natco settlement terms public?

The complete commercial terms, including any licensed launch date and supply arrangements, were not publicly disclosed in the case record sufficient to establish the full agreement.

References

Pfizer Inc. v. Natco Pharma Ltd., No. 1:21-cv-01179, U.S. District Court for the District of Delaware (2021-2023).

Pfizer Inc. (2024). 2023 annual report. https://www.pfizer.com/investors/financial-reports/annual-reports

Pfizer Inc. (2025). 2024 annual report. https://www.pfizer.com/investors/financial-reports/annual-reports

U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/